Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aspen Pharmacare HoldingsAPNHY -1.06%73 Debt-to-Equity is 0.41 as of Dec. 2025, which is 18% below its 10-year median of 0.50. GuruFocus rates APNHY with a GF Score™ of 73/100 and a GF Value™ of $10.03 (Modestly Undervalued). The stock has 10 warning signs investors should review. Among 815 Drug Manufacturers companies, Aspen Pharmacare Holdings ranks worse than 61.72% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Aspen Pharmacare Holdings's Debt-to-Equity or its related term are showing as below:
APNHY'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.31 Med: 0.5 Max: 1.21
Current: 0.41
During the past 13 years, the highest Debt-to-Equity Ratio of Aspen Pharmacare Holdings was 1.21. The lowest was 0.31. And the median was 0.50.
APNHY's Debt-to-Equity is ranked worse than 61.72% of 815
companies
in the Drug Manufacturers industry
Industry Median: 0.28
vs APNHY: 0.41
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Aspen Pharmacare Holdings Debt-to-Equity Related Terms
Aspen Pharmacare Holdings Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
APNHY vs ZTS, UTHR, VTRS: Debt-to-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Aspen Pharmacare Holdings's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aspen Pharmacare Holdings Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Aspen Pharmacare Holdings's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Aspen Pharmacare Holdings's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aspen Pharmacare Holdings (APNHY) has a Debt-to-Equity of 0.41 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Aspen Pharmacare Holdings and its competitors. This is 18% below median its historical median of 0.50. Over the past decade, Aspen Pharmacare Holdings' Debt-to-Equity has ranged from 0.31 to 1.21. According to the industry distribution chart, Aspen Pharmacare Holdings ranks #503 out of 815 companies in the Drug Manufacturers industry, placing it in the top 61.7%.
Is Aspen Pharmacare Holdings' Debt-to-Equity too high?
Aspen Pharmacare Holdings' current Debt-to-Equity of 0.41 is 18% below median its 10-year median of 0.50. Over the past 10 years, this metric has ranged from a low of 0.31 to a high of 1.21. The Drug Manufacturers industry median Debt-to-Equity is 0.28. Aspen Pharmacare Holdings' value of 0.41 is 46.4% above this industry median. Based on the distribution chart, Aspen Pharmacare Holdings ranks #503 out of 815 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Aspen Pharmacare Holdings has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Aspen Pharmacare Holdings' Debt-to-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Aspen Pharmacare Holdings ranks #503 out of 815 companies for Debt-to-Equity. This places Aspen Pharmacare Holdings in the lower half of its industry. The industry median Debt-to-Equity is 0.28. Aspen Pharmacare Holdings' value of 0.41 is 46.4% above this benchmark. Historically, Aspen Pharmacare Holdings' own Debt-to-Equity has ranged from 0.31 to 1.21 over the past decade. While the company's 10-year median is 0.50 vs. the industry median of 0.28, Aspen Pharmacare Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.28, based on 815 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aspen Pharmacare Holdings's current Debt-to-Equity of 0.41 is 46.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Aspen Pharmacare Holdings and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aspen Pharmacare Holdings's current Debt-to-Equity is 0.41, which is 18% below median its own 10-year median of 0.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aspen Pharmacare Holdings stock overvalued right now?
Based on GuruFocus' analysis, Aspen Pharmacare Holdings (APNHY) is currently considered Modestly Undervalued. The stock's GF Value™ is $10.03, compared to a current price of $8.89 — trading 11.4% below its estimated fair value. The current Debt-to-Equity is 0.41, which is 18% below median its 10-year median of 0.50 and 46.4% above the Drug Manufacturers industry median of 0.28. Aspen Pharmacare Holdings' overall GF Score™ is 73/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Aspen Pharmacare Holdings (APNHY), the current Debt-to-Equity is 0.41 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aspen Pharmacare Holdings (APNHY) Overvalued in 2026?
Based on GuruFocus' analysis, Aspen Pharmacare Holdings stock appears to be undervalued.
The current stock price of $8.89 is trading 11.4% below its estimated GF Value™ of $10.03.
GuruFocus considers Aspen Pharmacare Holdings to be Modestly Undervalued.
Key valuation signals for APNHY:
Debt-to-Equity: 0.41 (18% below median its 10-year median of 0.50)
GF Value™: $10.03 vs. price of $8.89 (11.4% below fair value)
Industry Position: 46.4% above the Drug Manufacturers median (#503 of 815)
No single metric tells the full story. See the APNHY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aspen Pharmacare Holdings Ltd is a multinational pharmaceutical company. The group focuses on marketing and manufacturing a broad range of post-patent, branded medicines and domestic brands covering both hospital and consumer markets. The business segments of the group are split between the Commercial Pharmaceuticals and Manufacturing segments. The Commercial Pharmaceuticals business segments are: Injectables, Over-the-counter, and Prescription. The Manufacturing business segments are: Active Pharmaceutical Ingredients, Finished Dose Form, and Heparin. Its geographic regions are Africa Middle East, Europe CIS, Australasia, Asia, and America.
73GF Score
Get the complete analysis for APNHY
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
APNHY has been successfully added to your 
